3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $23M | -$101M | -27.5% | -401.7% | — | $23M | $42571 |
| 2024 | $18M | -$7M | 9.7% | -33.9% | — | $23M | $1M |
| 2023 | — | -$3M | — | — | — | — | $1364 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$8M | 10.9% | -385.7% | — | $28M | $51730 |
| Dec '25 | $2M | -$28M | -470.2% | -1517.5% | — | $23M | $42571 |
| Sep '25 | $3M | -$34M | 7.7% | -1047.1% | — | $25M | $4M |
| Jun '25 | $8M | -$7M | 6.5% | -70.6% | — | $23M | $419942 |
| Mar '25 | $11M | -$32M | 6.4% | -288.6% | — | $24M | $3M |
| Dec '24 | $12M | -$4M | 10.1% | -30.2% | — | $23M | $1M |
| Sep '24 | $6M | -$2M | 9.2% | -30.8% | — | — | — |
| Jun '24 | $44540 | -$574325 | -5.9% | -1286.5% | — | — | — |
| Mar '24 | — | -$83122 | — | — | — | — | — |
How the market has priced WGRX against its own fundamentals since 2025-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Wellgistics Health, Inc.'s revenue has grown 28.7% per year. These are computed facts, not advice.
As of FY2025, Wellgistics Health, Inc. reported $23M of total debt against $42571 of cash; operating income covered interest expense -20.5×.
In FY2025, gross margin was -27.5%, operating margin -401.7%, and net margin -433.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.